215 related articles for article (PubMed ID: 11803442)
1. Cocaine, reward, movement and monoamine transporters.
Uhl GR; Hall FS; Sora I
Mol Psychiatry; 2002; 7(1):21-6. PubMed ID: 11803442
[TBL] [Abstract][Full Text] [Related]
2. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions.
Hall FS; Li XF; Sora I; Xu F; Caron M; Lesch KP; Murphy DL; Uhl GR
Neuroscience; 2002; 115(1):153-61. PubMed ID: 12401330
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference.
Sora I; Hall FS; Andrews AM; Itokawa M; Li XF; Wei HB; Wichems C; Lesch KP; Murphy DL; Uhl GR
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5300-5. PubMed ID: 11320258
[TBL] [Abstract][Full Text] [Related]
4. Intravenous cocaine induced-activity and behavioural sensitization in norepinephrine-, but not dopamine-transporter knockout mice.
Mead AN; Rocha BA; Donovan DM; Katz JL
Eur J Neurosci; 2002 Aug; 16(3):514-20. PubMed ID: 12193195
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms underlying the rewarding effects of cocaine.
Hall FS; Sora I; Drgonova J; Li XF; Goeb M; Uhl GR
Ann N Y Acad Sci; 2004 Oct; 1025():47-56. PubMed ID: 15542699
[TBL] [Abstract][Full Text] [Related]
6. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice.
Sora I; Wichems C; Takahashi N; Li XF; Zeng Z; Revay R; Lesch KP; Murphy DL; Uhl GR
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7699-704. PubMed ID: 9636213
[TBL] [Abstract][Full Text] [Related]
7. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice.
Budygin EA; John CE; Mateo Y; Jones SR
J Neurosci; 2002 May; 22(10):RC222. PubMed ID: 12006604
[TBL] [Abstract][Full Text] [Related]
8. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity.
Miller GM; Yatin SM; De La Garza R; Goulet M; Madras BK
Brain Res Mol Brain Res; 2001 Feb; 87(1):124-43. PubMed ID: 11223167
[TBL] [Abstract][Full Text] [Related]
9. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function.
Mateo Y; Budygin EA; John CE; Jones SR
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):372-7. PubMed ID: 14691264
[TBL] [Abstract][Full Text] [Related]
10. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Shimazu S; Tsunekawa H; Yoneda F; Katsuki H; Akaike A; Janowsky A
Eur J Pharmacol; 2003 Dec; 482(1-3):9-16. PubMed ID: 14659999
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.
Tamiz AP; Bandyopadhyay BC; Zhang J; Flippen-Anderson JL; Zhang M; Wang CZ; Johnson KM; Tella S; Kozikowski AP
J Med Chem; 2001 May; 44(10):1615-22. PubMed ID: 11334571
[TBL] [Abstract][Full Text] [Related]
12. Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization.
Zhou J; He R; Johnson KM; Ye Y; Kozikowski AP
J Med Chem; 2004 Nov; 47(24):5821-4. PubMed ID: 15537337
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.
Dutta AK; Fei XS; Beardsley PM; Newman JL; Reith ME
J Med Chem; 2001 Mar; 44(6):937-48. PubMed ID: 11300876
[TBL] [Abstract][Full Text] [Related]
14. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.
Morón JA; Brockington A; Wise RA; Rocha BA; Hope BT
J Neurosci; 2002 Jan; 22(2):389-95. PubMed ID: 11784783
[TBL] [Abstract][Full Text] [Related]
15. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.
Shen HW; Hagino Y; Kobayashi H; Shinohara-Tanaka K; Ikeda K; Yamamoto H; Yamamoto T; Lesch KP; Murphy DL; Hall FS; Uhl GR; Sora I
Neuropsychopharmacology; 2004 Oct; 29(10):1790-9. PubMed ID: 15226739
[TBL] [Abstract][Full Text] [Related]
16. Voltammetric assessment of dopamine clearance in the absence of the dopamine transporter: no contribution of other transporters in core or shell of nucleus accumbens.
Mateo Y; Budygin EA; John CE; Banks ML; Jones SR
J Neurosci Methods; 2004 Dec; 140(1-2):183-7. PubMed ID: 15589348
[TBL] [Abstract][Full Text] [Related]
17. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression.
Donovan DM; Miner LL; Perry MP; Revay RS; Sharpe LG; Przedborski S; Kostic V; Philpot RM; Kirstein CL; Rothman RB; Schindler CW; Uhl GR
Brain Res Mol Brain Res; 1999 Nov; 73(1-2):37-49. PubMed ID: 10581396
[TBL] [Abstract][Full Text] [Related]
18. Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters.
Kolhatkar R; Cook CD; Ghorai SK; Deschamps J; Beardsley PM; Reith ME; Dutta AK
J Med Chem; 2004 Oct; 47(21):5101-13. PubMed ID: 15456254
[TBL] [Abstract][Full Text] [Related]
19. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.
Froimowitz M; Wu KM; Moussa A; Haidar RM; Jurayj J; George C; Gardner EL
J Med Chem; 2000 Dec; 43(26):4981-92. PubMed ID: 11150168
[TBL] [Abstract][Full Text] [Related]
20. Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice.
Hall FS; Li XF; Randall-Thompson J; Sora I; Murphy DL; Lesch KP; Caron M; Uhl GR
Neuroscience; 2009 Sep; 162(4):870-80. PubMed ID: 19482066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
